Avecho Biotechnology Secures US and EU Patent Protection for CBD Insomnia Treatment Through 2040
核心洞察
Avecho Biotechnology (搜索) received patent allowances from the US Patent and Trademark Office and European Patent Office for its cannabidiol (CBD) TPM soft-gel capsule formulation, providing protection until at least 2040.
The company's CBD TPM capsule is currently in the largest global Phase III clinical trial for cannabidiol treatment of insomnia, with interim analysis of 210 patients expected in the first half of 2026.
The patent coverage extends beyond CBD to include other cannabinoid formulations, positioning Avecho for potential first-mover advantage in the Australian CBD insomnia market.
Avecho Biotechnology (搜索) (ASX: AVE) has secured significant patent allowances from both the US Patent and Trademark Office and the European Patent Office for its proprietary cannabidiol (CBD) TPM soft-gel capsule formulation. Once formally granted, these patents will provide protection for the company's tocopheryl phosphate mixture-based formulation until at least 2040.
The patent coverage extends beyond CBD to encompass formulations using other cannabinoids, creating opportunities for future commercialization beyond Avecho's core insomnia program. Chief executive officer Paul Gavin described the allowances as "an important milestone for Avecho," reinforcing the company's leadership position in cannabinoid formulation technology as it advances toward regulatory submissions.
Phase III Clinical Development
The CBD TPM capsule is currently undergoing evaluation in what the company describes as the largest global clinical trial of cannabidiol for insomnia. This pivotal Phase III, multi-centre, randomised, double-blind, placebo-controlled clinical trial was designed in consultation with international sleep and regulatory experts to meet the requirements of the Therapeutic Goods Administration (TGA), US Food and Drug Administration, and European Medicines Agency.
Avecho expects to conduct a planned interim analysis of the first 210 patients in the first half of 2026. The company believes positive results from this analysis will support a regulatory submission to the TGA. Notably, Avecho believes it has a potential first-mover advantage, as no other Phase III CBD insomnia trials in Australia have succeeded to date.
TPM Technology Platform
The company's tocopheryl phosphate mixture (TPM) drug-delivery system, derived from Vitamin E, has demonstrated the ability to improve solubility, stability, and absorption of active pharmaceutical ingredients across oral, dermal and transdermal applications. This technology platform forms the foundation of Avecho's broader pipeline, which includes TPM-enhanced injectable, oral, and topical products for human health, alongside ongoing development of TPM applications in animal health.
Market Opportunity
Regulatory changes introduced in Australia in 2020 now allow low-dose CBD products to be supplied without prescription once registered, potentially enabling over-the-counter pharmacy sales for Avecho's capsule upon approval. Market forecasts indicate the over-the-counter CBD segment in Australia could exceed US$125 million per annum locally.
The expanding patent protection across major markets strengthens Avecho's global commercial position as it advances the CBD TPM capsule toward registration. The company's diverse TPM applications and the broad scope of its patent coverage position it to capitalize on multiple cannabinoid-based therapeutic opportunities in the evolving regulatory landscape.